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Abstract
There is an increasing body of research documenting flaws in many published systematic reviews’ methodological
and reporting conduct. When good systematic review practice is questioned, attention is rarely turned to the
composition of the team that conducted the systematic review. This commentary highlights a number of relevant
articles indicating how the composition of the review team could jeopardise the integrity of the systematic review
study and its conclusions. Key biases require closer attention such as sponsorship bias and researcher allegiance,
but there may also be less obvious affiliations in teams conducting secondary evidence-syntheses. The importance
of transparency and disclosure are now firmly on the agenda for clinical trials and primary research, but the meta-biases
that systematic reviews may be at risk from now require further scrutiny.
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Main text
Systematic reviews benefit from team working, and
co-production is an essential part of high-quality re-
search synthesis and healthcare decision [1, 2]. However,
despite their reputation as transparent and rigorous prod-
ucts, they are influenced by the people who conduct them
and this in turn could affect the resulting conclusions. A
review team may comprise experienced systematic re-
viewers, information specialists, statisticians, and content
experts, or, as no licence is required to conduct a system-
atic review, the review team may include none of these
specialties. In this case, it may be wise to consider who is
conducting the systematic review and why. The number
of systematic reviews indexed in MEDLINE has increased
threefold over the last decade [3] indicating a steady
spread in their employment globally. However, as in
primary research, [4] systematic reviews can vary hugely
in their reporting quality or their methodological quality
[5–7]. Indeed, many systematic reviews are receiving in-
creasing criticism for failing to live up to their reputation
as high-quality, well-conducted pieces of research [8, 9].
They can be susceptible to bias, for example, when re-
views are conducted by people who have a stake in the
conclusions (researcher allegiance) [10, 11]. Alternatively,
reviews could be conducted carelessly, in the chosen
methods of meta-analysis or study selection (meta-bias)
[12], or by failing to report research misconduct even
when identified [13]. If flawed systematic reviews continue
to be published, they risk losing their eminent position in
the evidence hierarchy; therefore, closer examination of
who might be conducting them, and how the output can
be affected, is warranted.
Ordinarily, systematic reviews are conducted to sum-
marise evidence objectively for an intervention’s effective-
ness to decision-makers or to highlight where evidence to
support an intervention is lacking. Funding bodies often
require applicants of new primary research to reference an
existing systematic review or to review the relevant evi-
dence prior to commencing new clinical trials. A less
worthy motive for conducting a systematic review could
be simply to get something published, [14] whether affili-
ated to the intervention or not. But a more troubling
motive is that systematic reviews may be conducted and
published by people who have a clear stake in publishing
positive results. How can we know if the authors of a
systematic review are affiliated to the review question?
Despite the existence of guidelines and reporting stan-
dards for systematic reviews, it is not currently a require-
ment to declare the motives of the reviewers, i.e., who is
behind the origination of the review question (except for
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sponsored work) and whether the same people who set
the review question are also involved with answering the
review question. Information about whether the research
question originated from outside the review team, such as
through a commissioned call, are not currently deemed as
relevant to potential assessment of bias in systematic re-
views. Recent research by Borah et al. [15] indicates that
funded reviews took significantly longer to complete and
involved more authors and team members than studies
which did not report funding. A longer timeframe could
be indicative of increased rigour in funded reviews. The
same study authors also noted from inspection of 195
published reviews identified from the PROSPERO data-
base that the number of “team members” is also discrep-
ant from the number of authors of resulting publications.
Their findings indicate that by the time the review reaches
publication, there are more authors than people initially
registered. How might systematic reviews accrue authors
from protocol to final publication and should this be of
concern?
Whilst explicit and transparent a priori methods are a
hallmark of systematic reviews, in practice, they can be an
iterative process, with movement back and forth between
phases depending on the results obtained at each step.
Despite this flexibility, systematic review authors are re-
sponsible for ensuring transparency. A systematic review
protocol aims to ensure that necessary deviations from
planned methods are evidenced and ideally discussed by
the review team. However, even when methods are stated
a priori in systematic review protocols, deviations from
the protocol, whether justified or not, may be seldom
reported in the final publication, as highlighted by
Silagy et al. [16] who found 43 out of a sample of 47
published Cochrane reviews had undergone a major
change compared with the most recently published proto-
col. Moreover, Kirkham et al. [17] found discrepancies
between protocol and published reviews in a sample of
288 Cochrane reviews in the reported primary outcome.
The authors highlight this potential bias in the systematic
review process, with changes being made after knowledge
of the results of the individual trials. These findings relat-
ing specifically to Cochrane reviews indicate that even
when stringent guidelines are in place and content experts
are likely to be involved, adherence to good practice does
not necessarily always follow. Additionally, Page and col-
leagues [18] found when analysing 682 systematic reviews
(both Cochrane and non-Cochrane) that at least a third
did not report use of a systematic review protocol. This
means that substantial portions of systematic reviews are
being conducted without making an accountable public
record of the planned methods. Reporting guidelines are
in place for systematic reviews in the form of the PRISMA
statement [19, 20] to promote adherence to good practice,
but again, uptake of compliance with guidance from
systematic review authors is varied [7] and often poor.
Wasiak and colleagues [21] report that, from a review of
60 systematic reviews in burn care management, 13 of the
27 PRISMA checklist items were addressed in less than
50% of cases. Whilst journals may stipulate to authors that
the PRISMA checklist is followed when submitting sys-
tematic reviews for publication, peer reviewers and journal
editors may be unlikely to find the time to monitor or
regulate authors adherence to these guidelines, in addition
to reviewing the scientific and reporting quality of the
draft manuscript. The responsibility of maintaining good
practice in systematic reviews should reside with the
systematic review team. Awareness of relevant methodo-
logical guidelines and adherence to good practice may be
more likely in a review team comprising of at least one
experienced reviewer.
From protocol design to analysis, there are opportun-
ities for team members to shape the project and these
individual influences can affect the output [22]. Biases
may be fairly obvious such as highlighting the most
favourable results or perhaps more subtle and hard to
detect such as biases in study selection (into the review
or into the meta-analysis) towards positive studies. The
motives of the review team can influence whether
research findings represent true treatment effects and
are able to be replicated [23] such as financial or other
interests within the review team [12]. Ebrahim et al. [24]
conducted a study of 185 meta-analyses in antidepres-
sants to find that 29% of papers contained authors who
were employees of the assessed drug manufacturer and
that 79% had an industry link to the drug assessed. This
study also found that meta-analyses including an author
who was an employee of the manufacturer of the
assessed drug were 22 times less likely to have negative
statements about the drug than other meta-analyses.
Additionally, Gómez-García et al. [25] assessed 220
reviews to investigate the role of the funding source in
systematic reviews and meta-analyses in psoriasis. They
report that reviews containing a high number of authors
with conflicts of interest were of lower quality. Financial
”conflict of interest” (CoI) in systematic reviews has been
shown to influence the results of published systematic
review in the field of sugar-sweetened beverages and
weight gain or obesity [26]. This evidence collectively
suggests that a review team comprising individuals who
are known to have a stake in the outcome of the re-
view is a potential threat to the integrity of the report
(sponsorship bias).
However, standard CoI statements often focus on nar-
row commercial interests and may be inadequate to reveal
potentially hidden agendas [27]. Consumers of systematic
reviews cannot rely solely on declarations of competing
interests, which may relate to recent pecuniary funding
(within the last 3 years), as opposed to more long-term
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affiliations to health interventions, to know whether those
conducting the review have an interest in the results of
the research (researcher allegiance) [28]. For example, for
some, their very employment is reliant on a given inter-
vention’s reputation such as homoeopaths or psychothera-
pists and they are unsurprisingly unlikely to publish a
rigorous review with neutral or negative conclusions
underpinning the basis of their profession. A recent study
investigating the relationship between CoI and the conclu-
sions of systematic reviews of psychological therapies
found that “non-financial CoI” and particularly the inclu-
sion of own primary studies into reviews were frequently
seen in systematic reviews of psychological therapies [29].
Moreover, author allegiance to psychological therapy was
never disclosed in 15 out of 95 reviews. Similarly, despite
the apparent benefit that topic experts may bring to the
review team, Gotzsche and Ioannidis (2012) [30] point out
that the strong opinions of content area experts, such as
clinical experts, can make it difficult to perform unbiased
systematic reviews. For example, they assert that “people
who have an interest in concealing uncomfortable evi-
dence, clinicians, for example, find it particularly difficult
to acknowledge the harms their interventions may cause”.
Current methods for describing who is involved in the
conduct of systematic reviews and their level of affiliation
may occupy insufficient attention in final peer-reviewed
journal publications.
Objective research, such as secondary evidence synthe-
ses, should not necessarily be carried out dispassionately.
The contribution of user perspectives and lay-expert
engagement in research are now well-recognised [31].
Without patient and public involvement, due consider-
ation to whether the review question or the included
evidence are patient-centred may not be given [32]. In
addition, global collaboration benefits the visibility and
quality of scientific research activity [33], and failure to
work collaboratively between institutions can have a silo
effect on evidence synthesis projects supposedly deemed
to be at the forefront of evidence-based medicine [34].
However, methodologists with particular skill sets who
are not systematic reviewers such as statisticians and
modellers employed in systematic reviews may be likely
to recommend strategies which play to their strengths
and that they have employed in the past and possibly
without due consideration of other appropriate methods.
Systematic reviews that fail to accommodate complex
research questions may be at risk of being inflexible to
useful innovations due to a reliance of “tried and tested”
methodology [35]. For example, focusing on efficacy
studies rather than pragmatic trials may jeopardise the
external validity of review findings [36, 37]. Review
teams preoccupied with critiquing heterogeneity of the
existing evidence may be unlikely to elaborate on the
external validity of the review, e.g., by searching and
critiquing relevant grey literature, or service-user per-
spectives. Team experience or expertise could affect the
external validity of a systematic review therefore. For ex-
ample, research indicates that few strategies in the
Cochrane Collaboration explicitly address the research
priorities of disadvantaged populations and innovative
approaches are needed to ensure that the research prior-
ities of diverse stakeholders are considered [38, 39].
Equitable representation of population demographics
within the team, as well as the more obviously required
skills and experience may potentially influence the
importance and uptake of the review.
In summary, there are a variety of factors that may
influence the efficiency and appropriateness of the re-
view team in addition to ensuring that the team com-
prises individuals with experience in systematic reviews.
A well-trained methodological research workforce, con-
tinuing professional development, and involvement of
non-conflicted stakeholders may help to ensure reprodu-
cible, accurate findings [2, 40]. But there are some less
clear components underlying the nature and conduct of
a review that can be influenced by motive, bias or error
that may not be sufficiently addressed by current quality
assessment tools for systematic reviews such as AMSTAR
[41], GRADE [42, 43] and ROBIS [33] or explicitly evident
from CoI declarations. Therefore, closer attention to who
is conducting these secondary research projects, and why,
is required rather than relying on the methods and con-
clusions of systematic reviews to speak for themselves.
Systematic reviews are a powerful instrument in evidence-
based medicine and are arguably more cost-effective than
primary research [44]. But if systematic reviews are to
maintain their primacy, their methodology should evolve
through continued scrutiny in order to understand some
of the (un)seen biases that can influence reviews from the
review team composition, as well as the evidence that goes
into them.
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